Insider trade

CFO exercised or converted 823 CYTK derivative securities

Traded Jun 29, 2026 · Filed Jun 29, 2026

CytokineticsCYTK

823
Shares · @ $44.36

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 29, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 29, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000070

Filed / recorded

Jun 29, 2026, 9:23 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Sung Lee

Relationship

Officer

Officer title

EVP, Chief Financial Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jun 29, 2026

Transaction code

M

Shares / units

823

Price per share

$44.36

Acquired / disposed

Acquired (A)

Shares owned after

66,355

Ownership form

Direct

Amendment

No

Around the same time

Robert I BlumPresident & CEO

Filed 2mo ago

7,500Shares · @ $10.60

Traded Jul 27 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Robert I Blum (President & CEO) sold ~$607K of Cytokinetics

Planned saleFiled 2mo ago

Robert I BlumPresident & CEO

Filed 2mo ago

7,500Derivative units

Traded Jul 27 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record